跳至主要内容
临床试验/NCT00099892
NCT00099892已完成3 期

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Novartis Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 544 人开始时间: 2004年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
544
试验地点
2
主要终点
Change from baseline in HbA1c after 24 weeks

研究概览

简要总结

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, when added to metformin in people with type 2 diabetes who are not at target blood glucose levels on metformin alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 78 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Blood glucose criteria must be met
  • On a stable dose of metformin as defined by the protocol
  • Body mass index (BMI) in the range 22-45

排除标准

  • Type 1 diabetes
  • Pregnancy or lactation
  • Evidence of serious diabetic complications
  • Evidence of serious cardiovascular complications
  • Laboratory value abnormalities as defined by the protocol
  • Other protocol-defined exclusion criteria may apply

结局指标

主要结局

Change from baseline in HbA1c after 24 weeks

次要结局

  • Change from baseline in fasting plasma glucose at 24 weeks
  • Patients with endpoint HbA1c <7% after 24 weeks
  • Patients with reduction in HbA1c >/=to 0.7% after 24 weeks
  • Change from baseline in body weight at 24 weeks
  • Change from baseline in fasting lipids at 24 weeks

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验